Abstract
For over a decade, prenatal screening for cystic fibrosis (CF) has been considered a model for the integration of genetic testing into routine medical practice. Data from pilot studies and public policy discourse have led to recommendations by some professional organizations that CF screening should be offered or made available to pregnant women and their partners, and to couples planning a pregnancy. It is crucial that genetic counselors gain thorough understanding of the complexities of CF and the implications of positive test results, so that they may serve as a reliable, educated referral base and resource for health care providers and their patients. While not all pregnant women will be referred for genetic counseling prior to CF carrier testing, genetic counselors often will be asked to counsel clients after they have a positive test result, or who are found to be at increased risk. Genetic counselors can play an important role in providing accurate and current information as well as support for patients’ informed decisions. These recommendations were created by a multicenter working group of genetic counselors with expertise in CF and are based on personal clinical experience, review of pertinent English language medical articles, and reports of expert committees. The recommendations should not be construed as dictating an exclusive course of management, nor does the use of such recommendations guarantee a particular outcome. These recommendations do not displace a health care provider’s professional judgment based on the clinical circumstances of a particular client.
Similar content being viewed by others
References
Al-Kouatly, H. B., Chasen, S. T., Streltzoff, J., & Chervenak, F. A. (2001). The clinical significance of fetal echogenic bowel. Am J Obstet Gynecol, 185(5), 1035–1038.
American College of Obstetricians and Gynecologists, American College of Medical Genetics, National Institutes of Health (2001). Preconception and Prenatal Carrier Screening for Cystic Fibrosis: Clinical and Laboratory Guidelines Washington, DC: American College of Obstetricians and Gynecologists.
Asch, D. A., Hershey, J. C., Dekay, M. L., Pauly, M. V., Patoon, J. P., Jedriziewski, M. K., et al. (1998). Carrier screening for cystic fibrosis: Costs and clinical outcomes. Med Decis Making, 18, 202–212.
Bennett, R., Motulsky, A., Bittles. A., Hudgins, L., Uhrich, S., Doyle, D., et al. (2002a). Genetic counseling and screening of consanguineous couples and their offspring: Recommendations of the National Society of Genetic Counselors. J Genet Couns, 11(2), 97–119.
Bennett, R. L., Hart, K. A., O’Rourke, E., Barranger, J. A., Johnson, J., MacDermot, K. D., et al. (2002b). Fabry disease in genetic counseling practice: Recommendations of the National Society of Genetic Counselors. J Genet Couns, 11(2), 121-146.
Bernhardt, B. A., Chase, G. A., Faden, R. R., Geller, G., Hofman, K. J., Tambor, E. S., et al. (1996). Educating patients about cystic fibrosis carrier screening in a primary care setting. Arch Fam Med, 5, 336–340.
Bobadilla, J. L., Macek, M. Jr., Fine, J. P., & Farrell, P. M. (2002). Cystic fibrosis: A worldwide analysis of CFTR mutations–correlation with incidence data and application to screening. Hum Mutat, 19(6), 575–606.
Britto, M., Kotagal, U., Hornung, R., Atherton, H., Tsevat, J., & Wilmott, R. (2002). Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis. CHEST, 121, 64–72
Bromley, B., Doubilet, P., Frigoletto, F. D., Jr., Krauss, C., Estroff, J. A., & Benacerraf, B. R. (1994). Is fetal hyperechoic bowel on second-trimester sonogram an indication for amniocentesis? Obstet Gynecol, 83(5 Pt 1), 647–651.
Buller, A., Olson, S., Redman, J. B., Hantash, F., Chen, R., & Strom, C. M. (2004). Frequency of the cystic fibrosis 3199del6 mutation in individuals heterozygous for I148T. Genet Med, 6(2), 108–109.
Caskey, C. T., Kaback, M. M., & Beaudet, A. L. (1990). The American Society of Human Genetics statement on cystic fibrosis screening. Am J Hum Genet, 46(2), 393.
Chillon, M., Casals, T., Mercier, B., Bassas, L., Lissens, W., Silber, S., et al. (1995). Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens. N Engl J Med, 332, 1475–1480.
Chu, C.-S., Trapnell, B. C., Curristin, S., Cutting, G. R., & Crystal, R. G. (1993). Genetic basis of variable exon 9 skipping in cystic fibrosis transmembrane conductance regulator mRNA. Nat Genet, 3, 151–156.
Clayton, E. W., V. L. Hannig, J. P. Pfotenhauer, R. A. Parker, P. W. Campbell 3rd, & J. A. Phillips, 3rd (1996). Lack of interest by nonpregnant couples in population-based cystic fibrosis carrier screening. Am J Hum Gene, 58(3), 617–627.
Cuppens, H., Lin, W., Jaspers, M., Costes, B., Teng, H., Vankeerberghen, A., et al. (1998). Polyvariant mutant cystic fibrosis transmembrane conductance regulator genes. The polymorphic (Tg)m locus explains the partial penetrance of the T5 polymorphism as a disease mutation. J Clin Invest, 101(2), 487–496.
Cystic Fibrosis Foundation (2002). Annual Patient Registry Database.
Cystic Fibrosis Foundation (1997). Clinical Practice Guidelines.
Claustres, M., Guittard, C., Bozon, D., Chevalier, F., Verlingue, C., Ferec, C., et al. (2000). Spectrum of CFTR mutations in cystic fibrosis and in congenital absence of the vas deferens in France. Hum Mutat, 16, 143–156.
Dork, T., Dworniczak, B., Aulehla-Scholz, C., Wieczorek, D., Bohm, I., Mayerova, A., et al. (1997). Distinct spectrum of CFTR gene mutations in congenital absence of the vas deferens. Hum Genet, 100, 365–377.
Doherty, R. A., Palomaki, G. E., Kloza, E. M., Erickson, J. L., & Haddow, J. E. (1996). Couple-based prenatal screening for cystic fibrosis in primary care settings. Prenat Diagn, 16(5), 397–404.
Eng, C. M., Schechter, C., Robinowitz, J., Fulop, G., Burgert, T., Levy, B., et al. (1997). Prenatal genetic carrier testing using triple disease screening. JAMA, 278(15), 1268–1272.
Fanos, J. H., & Johnson, J. P. (1995). Barriers to carrier testing for adult cystic fibrosis sibs: The importance of not knowing. Am J Med Genet, 59(1), 85–91.
Fiel, S. B. (1996). Pulmonary function during pregnancy in cystic fibrosis: Implications for counseling. Curr Opin Pulm Med, 2(6), 462–465.
Garred, P., Pressler, T., Madsen, H. O., Frederikson, B., Svejgaard, A., Hoiby, N., et al. (1999). Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis. J Clin Invest, 104, 431-437.
Girodon, E., Cazeneuve, C., Lebargy, F., Chinet, T., Costes, B., Ghanem, N., et al. (1997). CFTR Gene Mutations in Adults with Disseminated Bronchiectasis. Eur J Hum Genet, 5, 149–155.
Grody, W. W., Cutting, G. R., Klinger, K. W., Richards, C. S., Watson, M. S., & Desnick, R. J. (2001). Laboratory standards and guidelines for population-based cystic fibrosis carrier screening. Genet Med, 3, 149–154.
Groman, J. D., Meyer, M. E., Wilmott, R. W., Zeitlin, P. L., & Cutting, G. R. (2002). Variant cystic fibrosis phenotypes in the absence of CFTR mutations. N Engl J Med, 347(6), 401-407.
Groman, J. D., Hefferon, T. W., Casals, T., Bassas, L., Estivill, X., Des Georges, M., et al. (2004). Variation in a repeat sequence determines whether a common variant of the cystic fibrosis transmembrane conductance regulator gene is pathogenic or benign. Am J Hum Genet, 74(1), 176–179.
Haddow, J. E. (1997). Editorial: Why the term “carrier screening“ should be abandoned. J Med Screen, 4, 1.
Haddow, J. E., Bradley, L. A., Palomaki, G. E., Doherty, R. A., Bernhardt, B. A., Brock, D. J. H., et al. (1999). Issues in implementing prenatal screening for cystic fibrosis: Results of a working conference. Genet Med, 1, 129–135.
Hartley, N. E., Scotcher, D., Harris, H., Williamson, P., Wallace, A., Crauford, D., et al. (1997). The uptake and acceptability to patients of cystic fibrosis carrier testing offered in pregnancy by the GP. J Med Genet, 34, 459–464.
Hill, L. M., Fries, J., Hecker, J., & Grzybek, P. (1994). Second-trimester echogenic small bowel: an increased risk for adverse perinatal outcome. Prenat Diagn, 14(9), 845–850.
Kere, J., Estivill, X., Chillon, M., Morral, N., Nunes, V., Noriooo, R., et al. (1994). Cystic fibrosis in a low-incidence population: Two major mutations in Finland. Hum Genet, 93(2), 162–166.
Kere, J., Norio, R., Savilahti, E., Estivill, X., & de la Chapelle, A. (1989). Cystic fibrosis in Finland: a molecular and genealogical study. Hum Genet, 83(1), 20–25.
Kere, B.-S., Rommens, J. M., Buchanan, J. A., Markiewicz, D., Cox, T. K., Chakravarti, A., et al. (1989). Identification of the cystic fibrosis gene: Genetic analysis. Science, 245, 1073–1080.
Kere, E., Rave-Harel, N., Augarten, A., Madgar, I., Nissim-Rafina, M., Yahav, Y., et al. (1997). A cystic fibrosis transmembrane conductance regulator splice variant with partial penetrance associated with variable cystic fibrosis presentation. Am J Respir Crit Care Med, 155, 1914–1920.
Kere, E., Reisman, J., Corey, M., Canny, G. J., & Levison, H. (1992). Prediction of mortality in patients with cystic fibrosis. New Engl J Med, 326(8), 1187–1191.
Kessler, D., Moehlenkamp, C., & Kaplan, G. (1996). Determination of cystic fibrosis carrier frequency for Zuni native Americans of New Mexico. Clin Genet, 49(2), 95–97.
Kiesewetter, S., Macek, M., Davis, C., Curristin, S. M., Chu, C. S., Graham, C., et al. (1993). A mutation in CFTR produces different phenotypes depending on chromosomal background. Nat Genet, 5, 274–277.
Kraus, C., Naehrlich, L., Mattes, S., & Reis, A. (2002). Routine analysis of the CFTR IVS(8)T polymorphism discloses two pathogenic mutations. Am J Hum Genet, 71(Suppl), A2215.
Kristidis, P., Bozon, D., Corey, M., Markiewicz, D., Rommens, J., Tsui, L. C., et al. (1992). Genetic determination of exocrine pancreatic function in cystic fibrosis. Am J Hum Genet, 50, 1178–1184.
Levenkron, J. C., Loader, S., & Rowley, P. T. (1997) Carrier screening for cystic fibrosis: Test acceptance and one year follow-up. Am J Med Genet, 73(4), 378–386.
Lissens, W., B. Mercier, H. Tournaye, M. Bonduelle, C. Ferec, S. Seneca, et al. (1996). Cystic fibrosis and infertility caused by congenital absence of the vas deferens and related clinical entities. Hum Reprod, 11, 55–80.
Loader, S., P. Caldwell, A. Kozyra, J. C. Levenkron, C. D. Boehm, H. H. Kazazian Jr., et al. (1996). Cystic fibrosis carrier population screening in the primary care setting. Am J Hum Genet, 59(1), 234–247.
Massie, R. J. H., Poplawski, N., Wilcken, B., Goldblatt, J., Byrnes, C., & Robertson, C. (2001). Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. Eur Respir J, 17, 1195–1200.
McIntosh, N., Gane, L., McConkie-Rosell, A., & Bennett, R. (2000). Genetic counseling for fragile X syndrome: Recommendations of the National Society of Genetic Counselors. J Genet Couns, 9(4), 303–325.
McKone, E. F., Emerson, S. S., Edwards., K. L., & Aitken, M. L. (2003). Effect of genotype on phenotype and mortality in cystic fibrosis: A retrospective cohort study. Lancet, 361, 1671-1676.
Male Infertility Best Practice Policy Committee of the American Urological Association, Inc. and the Practice Committee of the American Society for Reproductive Medicine (2001a). Report on Evaluation of the Azoospermic Male. American Urological Association, Inc., Baltimore, Maryland & American Society for Reproductive Medicine, Birmingham, Alabama.
Male Infertility Best Practice Policy Committee of the American Urological Association, Inc. and the Practice Committee of the American Society for Reproductive Medicine (2001b). Report on Optimal Evaluation of the Infertile Male. American Urological Association, Inc., Baltimore, Maryland & American Society for Reproductive Medicine, Birmingham, Alabama.
Mennie, M. E., Gilfillan, A., Compton, M. E., Liston, W. A., & Brock, D. J. (1993b). Prenatal cystic fibrosis carrier screening: factors in a woman’s decision to decline testing. Prenat Diagn, 13, 807–814.
Mennuti, M. T., Thomson, E., & Press, N. (1999). Screening for cystic fibrosis carrier state. Obstet Gynecol, 93(3), 456–461.
Mickle, J. E., & Cutting, G. R. (1998). Clinical implications of cystic fibrosis transmembrane conductance regulator mutations. Clin Chest Med, 19, 443–458.
National Institutes of Health Consensus Development Conference Statement. Genetic Testing for Cystic Fibrosis April 14–16, 1997.
Noone, P. G., & Knowles, M. R. (2001). ‘CFTR-opathies’: Disease phenotypes associated with cystic fibrosis transmembrane conductance regulator gene mutations. Respir Res, 2, 328-332.
Noone, P. G., C. A. Pue Z. Zhou, K. J. Friedman, E. L. Wakelink, M. Ganeshananthan, et al. (2000). Lung disease associated with the IVS8 5T allele of the CFTR gene. Am J Respir Crit Care Med, 162, 1919–1924.
Noone, P. G., Zhou, Z., Silverman, L. H., Jowell, P. S., Knowles, M. R., & Cohn, J. A. (2001). Cystic fibrosis gene mutations and pancreatitis risk: Relation to epithelial ion transport and trypsin inhibitor gene mutations. Gastroenterology, 121, 1310–1319.
Ogino, S., Wilson, R.B., & Grody, W W. (2004). Generalized Bayesian risk calculations for autosomal recessive disease when only one mutation is detected, incorporating test sensitivity and each parent’s ethnicity information: What if a fetus has echogenic bowel and one CFTR mutation? J. Med Genet, 41, e70.
Ormond, K. E., Mills, P. L., Lester, L. A., & Ross, L. F. (2003). Effect of family history on disclosure patterns of cystic fibrosis carrier status. Am J Med Genet, 15, 119C(1), 70–77.
Palomaki, G. E. (2004). Editorial: Prenatal screening for cystic fibrosis: An early report card. Genet Med, 6(3), 1.
Palomaki, G. E., FitzSimmons, S. C., & Haddow, J. E. (2004). Clinical sensitivity of prenatal screening for cystic fibrosis via CFTR carrier testing in a United States panethnic population. Genet Med, 6(5), 405–414.
Pignatti, P. F., C. Bombieri, M. Benetazzo, A. Casartelli, E. Trabetti, L. S. Gile, et al. (1996). CFTR gene variant IVS8-5T in disseminated bronchiectasis. Am J Hum Genet, 58, 889-892.
Rave-Harel, N., E. Kere, Nissim-Rafina, M., I. Madjar, R. Goshen, A. Augarten, et al. (1997). The molecular basis of partial penetrance of splicing mutations in cystic fibrosis. Am J Hum Genet, 60, 87–94.
Richards, C. S., L. A. Bradley, J. Amos, B. A. Allitto, W. W. Grody, A. Maddlena, et al. (2002). Standards and Guidelines for CFTR Mutation Testing. Genet Med, 4, 379–391.
Roberts, T., Schwarz, M. J., Kerr-Liddell, R., Hinks, J. L., & Super, M. (2003). Cascade carrier-testing in cystic fibrosis. Paediatr Respir Rev, 4(4), 293–298.
Rohlfs, E. M., Hallam, S. E., Booker, J. K., Silverman, L. M., Heim, R. A., & Allitto, B. A. (2003). The CFTR polyT 6T allele is associated with CAVD. Genet Med, 5, A157.
Rohlfs, E. M., Sugarman, E. A., Heim, R. A., & Allitto, B. A. (2001). Frequency of carriers of two cystic fibrosis mutations in an apparently unaffected adult population. Genet Med, 3, 237.
Rohlfs, E. M., Z. Zhou, E. A. Sugarman, R. A. Heim, R. G. Pace, M. R. Knowles, et al. (2002), The I148T CFTR allele occurs on multiple haplotypes: A complex allele is associated with cystic fibrosis. Genet Med, 4, 319–323.
Rosenstein, B. J., & Cutting, G. R. (1998) The diagnosis of cystic fibrosis: A consensus statement. Cystic Fibrosis Foundation Consensus Panel. J Pediatr, 132(4), 589–595.
Schlegel, P. N., J. Cohen, M. Goldstein, M. Alikani, A. Adler, B. R. Gilbert, et al. (1995). Cystic fibrosis gene mutations do not affect sperm function during in vitro fertilization with micromanipulation for men with bilateral congenital absence of vas deferens. Fertil Steril, 64(2), 421–426.
Schwind, E. L., Wolfe, M., Greendale, K., Misra, L. M., Pass, K. A., & Wallerstein, R. (1999). Cystic fibrosis carrier screening practices in an ethnically diverse region: Experience of the Genetic Network of the Empire State, Puerto Rico, and the U.S. Virgin Islands. Genet Test, 3(2), 215–218.
Sorenson, J. R., B. Cheuvront, DeVellis, B., N. Callanan, L. Silverman, G. Koch, et al. (1997). Acceptance of home and clinic-based cystic fibrosis carrier education and testing by first, second, and third degree relatives of cystic fibrosis patients. Am J Med Genet, 70(2), 121–129.
Strom, C. M., D. Huang, A. Buller, J. Redman, B. Crossley, B. Anderson, et al. (2002). Cystic fibrosis screening using the College panel: Platform comparison and lessons learned from the first 20,000 samples. Genet Med, 4, 289-296.
Sugarman, E. A., Rohlfs, E. M., Silverman, L. M., & Allitto, B. A. (2004). CFTR Mutation distribution among U.S. Hispanic & African American individuals: Evaluation in CF patient and carrier screening populations. Genet Med, submitted for publication.
Super, M., Schwarz, M. J., Malone, G., Roberts, T., Haworth, A., & Dermody, G. (1994). Active cascade testing for carriers of cystic fibrosis gene. BMJ, 308(6942), 1462–1467.
Tambor, E. S., Bernhardt, B. A., Chase, G. A., Faden, R. R., Geller, G., Hofman, K. J., et al. (1994). Offering cystic fibrosis carrier screening to an HMO population: Factors associated with utilization. Am J Hum Genet, 55, 626–637.
Taussig, L. M., Lobeck, C. C., Kattwinkel, J., & Di Sant’Agnese, P. A. (1972). Fertility in males with cystic fibrosis. N Engl J Med, 287(12), 586–589.
The Cystic Fibrosis Genotype-Phenotype Consortium (1993). Correlation between genotype and phenotype in patients with cystic fibrosis. N Engl J Med, 329(18), 1308–1313.
Trepanier, A., Ahrens, M., McKinnon, W., Peters, J., Stopfer, J., Grumet, S., et al. (2004). Genetic cancer risk assessment and counseling: Recommendations of the National Society of Genetic Counselors. J Genet Couns, 13(2), 83–114.
U.S. Congressional Office of Technology Assessment (OTA) (1992). “Cystic Fibrosis and DNA Tests: Implications of Carrier Screening.“ Washington: OTA.
U.S. Preventive Services Task Force. Chairman Harold C. Sox, Jr. (1995). Guide to Clinical Preventive Services, 2nd ed. Appendix A. U.S. Government Printing Office. Stock No. 017001005258.
Vintzileos, A. M., Ananth, C. V., Smulian, J. C., Fisher, A. J., Day- Salvatore, D., & Beazoglou, T. (1998). A cost effectiveness analysis of prenatal carrier screening for cystic fibrosis. Obstet Gynecol, 91, 529–534.
Wald, N. J., Morris, J. K., Rodeck, C. H., Haddow, J. E., & Palomaki, G. E. (2003). Cystic fibrosis: Selecting the prenatal screening strategy of choice. Prenat Diagn, 23(6), 474–483.
Watson, M. S., Cutting, G. R., Desnick, R. J., Driscoll, D. A., Klinger, K., Mennuti, M., Palomaki, G. E., Popovich, B. W., Pratt, V. M., Rohlfs, E. M., Strom, C. M., Richards, C. S., Witt, D. R., & Grody, W. W. (2004). Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. Genet Med, 6(5), 387–391.
Watson, M. S., Desnick, R. J., Grody, W. W., Mennuti, M. T., Popovich, B. W., & Richards, C. S. (2002). Cystic fibrosis carrier screening: Issues in implementation. Genet Med, 4, 407–409.
Witt, D. R., C. Schaefer, P. Hallam, S. Wi, B. Bulumberg, A. Fishbach, et al. (1996). Cystic fibrosis heterozygote screening in 5,161 pregnant women. Am J Hum Genet, 58, 823–835.
Yankaskas, J. R., & Aris, R. (2000). Outpatient care of the cystic fibrosis patient after lung transplantation. Curr Opin Pulm Med, 6(6), 551–557.
Yankaskas, J. R., Marshall, B. C., Sufian, B., Simon, R. H., & Rodman, D. (2004) Cystic fibrosis adult care: Consensus conference report. Chest, 125(1, Suppl), 1S–39S.
Zielenski, J. (2000). Genotype and phenotype in cystic fibrosis. Respiration 67(2), 117–133.
Zielenski, J., M. Corey, R. Rozmahel, D. Markiewicz, I. Aznarez, T. Casals, et al. (1999). Detection of a cystic fibrosis modifier locus for meconium ileus on human chromosome 19q13. Nat Genet, 22, 128–129.
Zoler, M. L. (2003). Still below target levels, Cystic Fibrosis Screening Soars OB/GYN NEWS 38 (6).
Author information
Authors and Affiliations
Consortia
Corresponding author
Rights and permissions
About this article
Cite this article
Langfelder-Schwind, E., Kloza, E., Sugarman, E. et al. Cystic Fibrosis Prenatal Screening in Genetic Counseling Practice: Recommendations of the National Society of Genetic Counselors. J Genet Counsel 14, 1–15 (2005). https://doi.org/10.1007/s10897-005-1496-5
Issue Date:
DOI: https://doi.org/10.1007/s10897-005-1496-5